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ABSTRACT 
Chronic inflammation during childhood often leads to impaired bone growth and 
reduced height in adulthood. Interleukin-1β (IL-1β), interleukin-6 (IL-6) and the 
tumour necrosis factor-α (TNF-α) are pro-inflammatory cytokines up-regulated during 
chronic inflammation. At the same time, experimental studies indicate that those 
cytokines affect growth by interfering with the Growth Hormone (GH)/Insulin-like 
Growth Factor I (IGF-I) axis. Moreover, IL-1β and TNF-α decrease murine bone 
growth in vitro by acting at the growth plate level. 
To counteract growth retardation in children with severe forms of JIA, GH 
therapy has been used, with beneficial effects on growth and final height in some 
patients. On the other hand, the introduction of biologic agents has revolutionized the 
treatment of rheumatoid arthritis in children and adults. Anti-TNF therapy not only 
decreases disease activity but may also improve growth in some juvenile idiopathic 
arthritis (JIA) patients. However, there is still a group of children in which the GH or 
anti-TNF therapy does not affect growth positively. For this reason, it is necessary to 
investigate new treatment strategies to prevent and/or treat growth failure in those 
patients. 
First, the effects of TNF-α antagonism on longitudinal growth in paediatric JIA 
patients were studied, differentiating any response from the normal pubertal growth 
spurt. From this study it can be concluded that TNF inhibition with etanercept (TNF 
soluble receptor) improves growth in a majority of JIA patients independent of puberty. 
Nevertheless, there are still patients who do not respond to TNF-inhibition and 
therefore are in need of alternative treatment modalities to optimize their growth. 
In the second study, it was hypothesized that biologic agents may rescue foetal 
rat metatarsal bones from cytokine-induced growth impairment and that IGF-I may 
potentiate such an effect. Indeed, both anakinra (IL-1 receptor antagonist) and 
etanercept efficiently and dose-dependently prevent cytokine-induced bone growth 
impairment in cultured bones. Combinations of anakinra or etanercept with IGF-I 
further improved bone growth. 
In the third study, it was found that IL-1β and TNF-α are produced by growth 
plate chondrocytes and that both cytokine antagonists improve growth of cultured 
foetal rat metatarsal bones suggesting that these cytokines play a physiological role in 
the normal regulation of longitudinal bone growth. 
In the fourth study, the local effects of IL-6 on growth plate chondrocytes of 
foetal rat metatarsal bones were studied. It was found that in the presence of its 
receptor, IL-6 decreases in vitro bone growth and it further suppresses growth when 
combined with IL-1β or TNF-α. Furthermore, IL-6 is produced by growth plate 
chondrocytes in vitro after stimulation with IL-1β+TNF-α, which may partially explain 
the synergistic inhibitory effect of those cytokines on murine bone growth. 
In conclusion, pro-inflammatory cytokines, normally up-regulated in children 
suffering from chronic inflammatory diseases, act in a synergistic way targeting growth 
plate chondrocytes and thereby decrease longitudinal bone growth. Biological agents 
blocking the actions of pro-inflammatory cytokines may improve bone growth.  
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1 INTRODUCTION 
 
1.1 ENDOCHONDRAL OSSIFICATION 
Longitudinal bone growth is the result of a process called endochondral 
ossification, by which the embryonic cartilaginous model of most bones is gradually 
replaced by calcified bone. During endochondral ossification, chondrocytes proliferate, 
undergo hypertrophy and die; the cartilage extracellular matrix they construct is then 
invaded by blood vessels, bone marrow cells, osteoclasts and osteoblasts, the last of 
which deposit bone matrix on remnants of cartilage matrix (Mackie, Ahmed et al. 
2008). 
Bone growth is influenced by several autocrine/paracrine and endocrine factors, 
which will be briefly presented and illustrated in Figure 1. 
 
1.1.1 Autocrine/paracrine regulators of growth 
 
1.1.1.1 Wingless-type MMTV integration site family (WNTs) 
WNTs are expressed in the surrounding tissue of the early mesenchymal 
condensations that will become the cartilage template of the new bone (Guo, Day et al. 
2004). High WNT signalling enhances direct ossification of mesenchymal cells 
whereas low WNT signalling allows chondrogenesis and subsequent endochondral 
bone formation (Day, Guo et al. 2005). 
 
1.1.1.2  Bone Morphogenetic Proteins (BMPs) 
BMP signalling is crucial for endochondral ossification because it promotes 
commitment of mesenchymal cells into the chondrogenic lineage, as well as 
proliferation and survival of chondrocytes in the cartilage anlagen (Yoon, Ovchinnikov 
et al. 2005). 
 
1.1.1.3  Fibroblast Growth Factors (FGFs) 
FGF signalling decreases the rate of chondrocyte proliferation whereas it 
stimulates hypertrophic differentiation. FGF antagonizes BMP signalling in the control 
of chondrocyte proliferation. FGFs are produced by cells in the perichondrium while 
FGFRs are expressed in proliferative and hypertrophic chondrocytes (Minina, Kreschel 
et al. 2002). 
 
1.1.1.4 Indian Hedgehog (IHH) 
IHH is considered the master regulator of both chondrocyte and osteoblast 
differentiation during endochondral bone formation (Kronenberg 2003). IHH is 
expressed in cells undergoing the transition from proliferating to hypertrophic 
chondrocytes. The receptors for IHH are located in the perichondral region flanking the 
IHH expression domain, extending slightly further toward the end of the cartilage 
elements; however, periarticular epiphysial chondrocytes respond to IHH stimulation 
by synthesizing PTHrP. PTHrP then acts on proliferative chondrocytes to inhibit their 
differentiation into hypertrophic chondrocytes, thus forming a feedback loop that 
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stabilizes the rate of chondrocyte differentiation, and consequently, the height of the 
proliferative columns (Vortkamp, Lee et al. 1996).  
In addition, IHH signalling on the perichondral cells adjacent to the IHH-
producing prehypertrophic cells of the growth plate induce them to convert to 
osteoblasts, which form part of the primary ossification centre (St-Jacques, 
Hammerschmidt et al. 1999). 
 
1.1.1.5 Parathyroid hormone related protein (PTHrP) 
PTHrP is expressed by periarticular epiphysial chondrocytes of the growth plate 
and plays a fundamental role in keeping proliferating chondrocytes in the proliferative 
stage. The PTH/PTHrP receptors (PPRs) are expressed at low levels by proliferating 
chondrocytes and at high levels by prehypertrophic/early hypertrophic chondrocytes. 
Under PTHrP signalling, chondrocytes keep proliferating in the proliferative pool. 
When chondrocytes are no longer sufficiently stimulated by PTHrP, they stop 
proliferating and synthesize IHH (Vortkamp, Lee et al. 1996; Kronenberg 2003). 
 
1.1.1.6 Components of the extracellular matrix 
The ECM of the growth plate cartilage is composed mainly of collagens and 
proteoglycans, but it also contains other non-collagenous proteins. Collagen type II is 
the major collagen in cartilage, and it is present throughout the growth plate, whereas 
collagen type X is expressed only in the hypertrophic zone (Hausler, Helmreich et al. 
2002). 
Collagen type II is of foremost importance, because without it, endochondral 
ossification would not occur (Talts, Pfeifer et al. 1998). In addition, proteolytic 
degradation of collagen type II induces chondrocyte hypertrophy as well as expression 
of MMP-13 (collagenase 3) (Tchetina, Kobayashi et al. 2007), which is crucial for 
remodelling the ECM in the transition zone of the growth plate. MMP-13 induces 
collagen type II degradation, chondrocyte differentiation, collagen type X synthesis and 
calcium incorporation (Wu, Tchetina et al. 2002). 
Another metalloproteinase, MMP-9 (gelatinase B) is highly expressed in 
osteoclasts and it promotes apoptosis, vascularization and ossification of the 
hypertrophic cartilage (Vu, Shipley et al. 1998). VEGF is an angiogenic factor 
expressed in hypertrophic chondrocytes which works on specific receptors located in 
the perichondrium promoting migration of endothelial cells towards the GP cartilage 
(Zelzer, Glotzer et al. 2001). 
In contrast, tissue inhibitor of metalloproteinases (TIMPs) are expressed 
throughout the growth plate to modulate the effect of MMPs (Haeusler, Walter et al. 
2005). 
The components of cartilage matrix are not only important for their structural 
roles, but some also exert specific receptor mediated effects on cell behaviour. Integrins 
are receptors that mediate chondrocyte-matrix interactions; without them, chondrocytes 
are smaller, unable to differentiate, undergo apoptosis and in general, bone growth is 
stunted (Hirsch, Lunsford et al. 1997). 
 
 
 
 
   3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Endocrine and paracrine/autocrine factors that regulate endochondral ossification. 
Longitudinal bone growth occurs at the growth plate (GP) by endochondral ossification. The GP contains 
only one cell type, the chondrocyte, at different levels of differentiation, distributed within the resting 
(RZ), proliferative (PZ) and hypertrophic (HZ) zones. Numerous endocrine and paracrine/autocrine 
factors regulate the different processes that take place during endochondral ossification; i.e. 
chondrogenesis; proliferation; hypertrophy; extracellular matrix (ECM) synthesis/mineralization; 
apoptosis and ossification. 
GCs: Glucocorticoids; GH: Growth Hormone; IGFs: Insulin-like Growth Factors; WNTs: Wingless-type 
mouse mammary tumour virus integration site family; BMPs: Bone Morphogenetic Proteins; PTHrP: 
Parathyroid hormone related protein; FGFs: Fibroblast Growth Factors; IHH: Indian Hedgehog; MMP: 
matrix metalloproteinase. 
 
1.1.2 Endocrine regulators of growth 
 
1.1.2.1  Glucocorticoids (GCs) 
GCs play an important role in early development, but the constant exposure to 
GCs in chronic inflammatory diseases is detrimental to longitudinal bone growth 
(Simon, Fernando et al. 2002). In vitro experiments have shown that the GC 
dexamethasone directs the differentiation of stem cells into mature chondrocytes by 
upregulation of Sox9, the transcription factor that determines chondrogenesis (Locker, 
Kellermann et al. 2004). On the other hand, it inhibits GP’s chondrocyte proliferation 
by impairing the GH-induced stimulation of local secretion and paracrine action of 
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IGF-I (Jux, Leiber et al. 1998) and it stimulates chondrocyte apoptosis mainly in 
terminal hypertrophic chondrocytes concomitantly with a reduction in PTHrP 
expression (Chrysis, Ritzen et al. 2003). 
 
1.1.2.2 Growth Hormone (GH) 
GH has been known for many years to be an important endocrine regulator of 
longitudinal growth. The indirect actions of GH on longitudinal bone growth are 
mediated by IGF-I, which was formerly known as sulphation factor or somatomedin 
(Salmon and Daughaday 1957; Daughaday, Hall et al. 1972; Klapper, Svoboda et al. 
1983), which may be produced systemically (mainly in the liver) or locally by GP 
proliferative chondrocytes (Nilsson, Isgaard et al. 1986). 
However, direct actions of GH at the GP level have been suggested, as the 
growth hormone receptor (GHR) is expressed by GP chondrocytes (Cruickshank, 
Grossman et al. 2005). GH may act directly on the growth plate resting zone to promote 
generation of chondrocyte precursors, as suggested by experiments in which ghr gene 
deletion decreased both number and size of growth plate chondrocytes, in contrast to 
Igf1 null mice which exhibited only reduced chondrocyte size. This observation does 
not discard the possibility, however, that GH actions are mediated by local production 
of IGF-II, which is elevated in igf1 null mice (Wang, Zhou et al. 2004).  
 
1.1.2.3  Insulin-like Growth Factors (IGFs) 
The insulin-like growth factor (IGF) system plays an essential role in the 
regulation of cell growth, proliferation and survival, and affects nearly every organ 
system in the body. This family includes three ligands (IGF-I, IGF-II and insulin), their 
cell surface receptors (IGF-IR, M6P/IGF-IIR, IR and the hybrid IR/IGF-IR), six high 
affinity binding proteins (IGFBP-1 to 6) which prolong the half-life of the IGFs and 
modulate their bioavailability and activity, and the IGFBP proteases (Annunziata, 
Granata et al. 2011). 
The two major pathways that are activated by the IGF-1R are the MAPK 
(specifically ERK-1/2) and the PI3-K pathways. The ERK-1/2 pathway is associated 
with cell proliferation, because of its ability to drive the cyclin loop; whereas the PI3-K 
pathway is associated with enhancing specific cellular events, including hypertrophy 
and differentiation (O'Connor, McCusker et al. 2008). 
The metabolic actions of IGF-I on growth plate ECM synthesis and chondrocyte 
proliferation were long time ago recognized (Salmon and DuVall 1970). IGF-I is 
produced by GP proliferative chondrocytes even in the absence of systemic GH 
stimulus (Nilsson, Isgaard et al. 1986), highlighting the autocrine/paracrine role of this 
growth factor. 
 
1.1.2.4 Leptin 
Leptin is a hormone secreted mainly by white adipose tissue that regulates the 
appetite and therefore body weight (Cinti, Frederich et al. 1997). The leptin receptor, 
OB-R, shows many features of the class I cytokine receptor, and it is expressed in 
several tissues such as the lung and kidney but also the choroid plexus and 
hypothalamus (Tartaglia, Dembski et al. 1995). Moreover, OB-R is expressed in 
cartilaginous skeletal growth centres in which leptin enhances chondrocyte 
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proliferation and ECM synthesis in parallel with increased IGF-1 receptor levels (Maor, 
Rochwerger et al. 2002). In addition, leptin acts systemically by stimulating GH 
secretion in pituitary cells (Accorsi, Munno et al. 2007). 
 
1.1.2.5 Estrogens 
Increased levels of estrogen during puberty results in an initial growth spurt 
followed by growth plate fusion in both young men and women. Experimental studies 
in rabbits have shown that estrogen accelerates the process of chondrocyte 
proliferation, advancing GP senescence (exhaustion of the proliferative capacity of GP 
chondrocytes, accompanied by a reduction in the size of chondrocytes) followed by GP 
fusion. The increased proliferation upon estrogen treatment is accompanied by 
increased levels of IGF-I, suggesting the involvement of the GH/IGF-I axis (Weise, 
De-Levi et al. 2001). 
 
1.1.2.6  Androgens 
Most of the effects of androgens on bone growth are mediated through estrogen, 
as hypertrophic growth plate chondrocytes express aromatase P450 (CYP19), which 
converts testosterone into estrogen (Oz, Millsaps et al. 2001). 
Androgens may stimulate longitudinal growth through direct effects on GP, as 
dihydrotestosterone, a non-aromatizable androgen, can stimulate proliferation and 
differentiation in GP chondrocytes. This effect is linked to IGF-I upregulation (Krohn, 
Haffner et al. 2003). However, androgens do not affect growth in foetal rat metatarsal 
bones, despite the expression of androgen receptors in this model (Chagin, Vannesjo et 
al. 2009). 
 
1.1.2.7 Thyroid hormone 
Thyroid hormone inhibits proliferation, whereas it stimulates hypertrophic 
differentiation of GP chondrocytes by interacting with thyroid hormone receptors (TRs) 
expressed mainly in resting and proliferative chondrocytes, but which can also be found 
in prehypertrophic GP chondrocytes (Robson, Siebler et al. 2000). Both 
triiodothyronine (T3, the active form of thyroid hormone) and thyroxine (T4, the pro-
hormone) are capable of inducing chondrocyte differentiation, as the deiodinases that 
catalyze the conversion of T4 into T3 are expressed in the GP (Miura, Tanaka et al. 
2002). Furthermore, T3 inhibits PTH/PTHrP receptor mRNA expression in the ATDC5 
chondrogenic cell line, suggesting indirect actions as well. 
  
1.1.2.8  Retinoids 
The effects of retinoic acid (vitamin A) deficiency (Wolbach and Hegsted 1952) 
and excess (Wolbach and Hegsted 1953) on GP chondrocyte maturation, 
mineralization, vascularization and bone growth have long since been observed. 
Different retinoid receptors (RARs) are expressed throughout the GP but mainly in HZ 
and perichondrium. On the other hand, endogenous retinoids are expressed in 
perichondrium (Koyama, Golden et al. 1999). Retinoic acid activates the promoter of 
collagen type X, demonstrating the direct effect of retinoids on chondrocyte 
differentiation (Cohen, Lassova et al. 2006). 
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1.1.2.9  Vitamin D 
Vitamin D is the major regulator of mineral homeostasis. Vitamin D deficiency 
in children (rickets) leads to impaired longitudinal bone growth associated with 
increased GP HZ and defective GP mineralization. The HZ widening is the result of 
defective apoptosis of hypertrophic chondrocytes in parallel to normal proliferation 
(Donohue and Demay 2002). Moreover, in vitro studies have revealed that calcitriol 
(vitamin D3, the active metabolite) induces proliferation of cultured GP chondrocytes 
via stimulation of local IGF-I synthesis (Krohn, Haffner et al. 2003).  The direct effects 
of vitamin D at the growth plate level are mediated by vitamin D receptors (VDR) 
expressed in GP chondrocytes, to promote vascularization and osteoclastogenesis 
(Masuyama, Stockmans et al. 2006). 
 
 
1.2 CHRONIC INFLAMMATION AND GROWTH 
It has long been observed that children who suffer from chronic inflammatory 
diseases such as JIA or IBD, CRF, cystic fibrosis, or diabetes often experience growth 
retardation and decreased adult height (Czernichow 2009). In JIA, the prevalence of 
short stature ranges from 10.4% in children with the polyarticular form to 41.0% in 
patients with the systemic form (Gaspari, Marcovecchio et al. 2011). In the same way, 
growth failure is temporary in 40-50% of IBD cases, but can be prolonged in 10-20% 
in sufferers of CD (Cezard, Touati et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The pathophysiology of growth in chronic inflammatory diseases. 
Malnutrition, GC therapy and elevated circulating levels of pro-inflammatory cytokines are factors that 
contribute to the growth retardation observed in children suffering chronic inflammatory diseases. They 
may affect bone growth both systemically and locally at the growth plate level. 
IL: Interleukin; GC: Glucocorticoid; GH: Growth Hormone; IGF-I: Insulin-like Growth Factor. 
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Possible pathways leading to growth retardation in chronic diseases include 
caloric deprivation, due to too little substrate available to the child or an excessive need 
for and an overconsumption of substrate, as well as the inefficient management of body 
components needed for growth (Underwood 1999). In addition, long-term GC therapy 
contributes to the pathogenesis of growth retardation (Simon, Fernando et al. 2002). 
Nevertheless, growth impairment is also observed in systemic and polyarticular JIA 
patients who have never received corticosteroid treatment (Polito, Strano et al. 1997) 
and  malnutrition accounts for 60% of the final growth impairment in a rat model of 
colitis, leaving the remaining loss in growth to the inflammatory process itself 
(Ballinger, Azooz et al. 2000). 
The most common up-regulated pro-inflammatory cytokines found in tissues or 
biological fluids from IBD (Funakoshi, Sugimura et al. 1998) or JIA (Mangge, Kenzian 
et al. 1995; Kutukculer, Caglayan et al. 1998; Yilmaz, Kendirli et al. 2001; Saxena, 
Aggarwal et al. 2005; Macrae, Wong et al. 2007) patients are IL-1β, TNF-α and IL-6, 
and they can affect growth both systemically, by disrupting the GH/IGF-I axis, or 
locally, at the growth plate level. 
Figure 2 illustrates the pathophysiology of growth during chronic inflammatory 
diseases. 
 
1.2.1 Systemic effects of IL-1β, TNF-α and IL-6 on the GH/IGF-I axis 
It has been shown that the pro-inflammatory cytokine IL-6 is not only produced 
by immune cells but also by the folliculostellate cells in the normal anterior pituitary 
(Spangelo, MacLeod et al. 1990), and it stimulates GH secretion in a paracrine manner 
(Mainardi, Saleri et al. 2002). However, transgenic mice over-expressing IL-6 exhibit a 
defective growth phenotype associated with decreased IGF-I levels, yet normal GH 
production (De Benedetti, Alonzi et al. 1997). The decreased levels of IGF-I appear to 
be secondary to decreased IGFBP-3 levels and thereby increased IGF-I clearance (De 
Benedetti, Meazza et al. 2001). Moreover, these mice exhibit reduced trabecular and 
cortical bones and smaller GPs, with reduced HZs and impaired development of 
ossification centres as well as decreased osteoblast but increased osteoclast activity (De 
Benedetti, Rucci et al. 2006). On the other hand, in a rat model of colitis, growth 
impairment is related to increased levels of IL-6 and GH but decreased levels of IGF-I 
and IGFBP-3 as compared to controls (Ballinger, Azooz et al. 2000) indicating a state 
of GH resistance. 
Regarding TNF-α, this cytokine up-regulates both IL-6 and GH mRNA 
expression in ovine pituitary cell cultures (Nash, Brandon et al. 1992); however, GH 
production is decreased when pituitary cells are co-cultured with TNF-α and galanin, a 
peptide synthesized in GHRH neurons involved in the physiological regulation of GH 
secretion. Transgenic mice over-expressing the human TNF-α develop an erosive 
polyarthritis and exhibit reduced growth (Li and Schwarz 2003). 
Regarding IL-1β, it stimulates GH release from pig pituitary cells in vitro 
(Mainardi, Saleri et al. 2002) probably by stimulation of interleukin-6 release 
(Spangelo, Jarvis et al. 1991; Spangelo, Judd et al. 1991); but in combination with 
galanin, GH is decreased. Interestingly, reduction in IL-1 signalling by IL-1R1 
suppression or central IL-1Ra over-expression in mice result in a low bone mass 
phenotype, including bone growth impairment associated with increased 
osteoclastogenesis (Bajayo, Goshen et al. 2005). 
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Finally, both IL-1β and TNF-α have been shown to induce a state of GH 
resistance as both cytokines synergize in an additive way to decrease GHR expression 
and IGF-I production in primary cultures of rat hepatocytes (Wolf, Bohm et al. 1996).  
 
1.2.2 Local effects of IL-1β, TNF-α and IL-6 at the GP level 
Our group demonstrated the first evidence that IL-1β and TNF-α act locally, at 
the growth plate level, to inhibit longitudinal growth in cultured foetal rat metatarsal 
bones (Martensson, Chrysis et al. 2004). This observation was corroborated later when 
IL-1β and TNF-α again inhibited longitudinal growth in postnatal mouse metatarsals 
cultured in vitro (MacRae, Farquharson et al. 2006). The mechanisms behind growth 
retardation in those experiments included decreased chondrocyte proliferation and 
hypertrophy and increased apoptosis (Martensson, Chrysis et al. 2004; MacRae, 
Farquharson et al. 2006). 
In vitro studies have shown that IL-1β decreased proliferation and sulphate 
incorporation but increased collagen production and alkaline phosphatase activity in 
cells derived from the RZ of rat costochondral cartilage (Horan, Dean et al. 1996). 
Additional studies in the murine chondrogenic ATDC5 cell line demonstrated that both 
IL-1β and TNF-α decrease the synthesis of ECM components such as Collagen II, X 
and aggrecan (MacRae, Farquharson et al. 2006). 
In the previously mentioned studies, IL-6 had no effect on chondrocytes or 
growth; however, in a posterior study in cultured ATDC5 cells, IL-6 inhibited early 
differentiation and reduced the expression of type II collagen, aggrecan and type X 
collagen, when it was added earlier in culture (Nakajima, Naruto et al. 2009). 
The receptors for IL-1β and TNF-α: IL-1R1 and TNF-R1, respectively, are 
expressed by GP chondrocytes in foetal rat metatarsal bones at all levels of 
differentiation (Martensson, Chrysis et al. 2004). Moreover, TRAF, an adaptor protein 
for both IL-1R1 and TNF-R1, regulates cell survival, differentiation and proliferation 
by the activation of downstream effectors including NF-kB and MAPKs. Among the 
MAPKs, pro-inflammatory cytokines induce mainly p38 MAPK and JNK; however, 
ERK1/2 may also be induced by TNF-R1 and IL-1R1 activation (O'Connor, McCusker 
et al. 2008). 
On the other hand, IGF-IR is also expressed by GP chondrocytes in growing rats 
at all levels of differentiation (Cruickshank, Grossman et al. 2005). It is possible that 
receptors for both cytokines and growth factors are co-expressed in GP chondrocytes, 
which would result in intracellular crosstalk, as ERK1/2 is a common intracellular 
signalling component among the distinct ligand-activated pathways; thereby inducing a 
state of IGF-I or cytokine resistance (O'Connor, McCusker et al. 2008). 
 
1.3 GROWTH PROMOTING THERAPIES TARGETING THE GH/IGF-I AXIS 
Children with JCA suffering growth impairment exhibited low IGF-I levels but 
low to normal GH secretion which was not correlated to the IGF-I levels, irrespectively 
of GC treatment or disease’s subtype (Allen, Jimenez et al. 1991). In that study, the 
authors suggested that those children may present a state of IGF-I resistance and that 
reconstitution of IGF-I levels by means of improved nutrition and a better control of the 
disease activity should be prioritized before any GH intervention. Nevertheless, in a 
placebo-controlled cross-over study of children with JCA and severe growth 
retardation, GH treatment increased growth velocity in the majority of patients 
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independently of the initial GH status (Saha, Haapasaari et al. 2004). Furthermore, GH 
treatment was effective as well in children with severe JIA and under GC therapy, with 
improved height velocity and lean mass, although no benefit on fat and bone mass was 
observed in this study (Simon, Prieur et al. 2007). 
Even though GH treatment is beneficial in most growth-retarded JIA patients, the 
extent of disease activity have a significant influence on height outcome, since those 
patients with a moderate disease activity are the most profited from GH treatment 
(Bechtold, Ripperger et al. 2007). For that reason, new treatment strategies are needed 
to promote growth in those patients with severe inflammation. 
 
1.4 NEW IMMUNO-MODULATORY BIOLOGICAL DRUGS 
Immunomodulatory biological drugs targeting IL-1β, TNF-α or IL-6 are potential 
therapies that could restore longitudinal bone growth in children suffering chronic 
inflammatory diseases. 
 
1.4.1 Anti-TNF agents 
Etanercept is a recombinant fusion protein based on the p75-receptor for TNF 
(TNF-R2) and the Fc-part of human igG1. It acts as a soluble receptor through 
competitive inhibition of the TNF-receptor on the cell surface, thereby diminishing 
TNF-driven inflammation which plays a key role in the arthritic process. Etanercept is 
approved for the use in paediatric patients suffering from JIA (Enbrel® 2008). In 
patients with polyarticular JIA, it leads to a significant decrease in disease activity with 
sustained improvement and few side-effects as verified in an eight-year follow-up study 
(Lovell, Reiff et al. 2008). 
Other TNF antagonists are: Infliximab (Remicade®, a chimeric anti-TNF 
antibody) and adalimumab (Humira®, a fully human anti-TNF antibody). To detect 
the potential off-target activities of the three TNF inhibitors clinically used, protein 
biochips containing a printed serial dilution of TNF-α and about 384 different human 
proteins were used. Infliximab showed the highest degree of specificity, whereas 
adalimumab and etanercept showed more potential off-target binding events (Feyen, 
Lueking et al. 2008). 
Even though anti-TNF agents have revolutionized RA treatment in adults and 
children, other DMARDs, such as methotrexate, are still used as a first choice or in 
concomitance to anti-TNF drugs in JIA children. However, this anti-metabolite that 
inhibits the purine synthesis enzyme, dihydrofolate reductase, has proven to decrease 
bone growth in young rats through its direct effects on the GP-- including decreased 
chondrocyte and osteoblast proliferation and collagen type II expression, as well as 
increased chondrocyte and osteocyte apoptosis (Xian, Cool et al. 2007). 
On the contrary, improved bone growth has been reported in JIA patients treated 
with either etanercept or other TNF-antagonists. In a small mixed population (n=7) of 
prepubertal and pubertal girls with refractory JIA and growth retardation, etanercept 
treatment improved both disease activity and growth. Those effects were accompanied 
by a discontinuation of oral GCs, a reduction of circulating IL-6 and increased levels of 
IGF-I and IGFBP-3 (Schmeling, Seliger et al. 2003). Furthermore, etanercept improved 
bone mineral status in 15 out of 20 JIA children who responded to etanercept after one 
year of treatment regarding the control of disease activity, in contrast to the ones who 
did not respond (Simonini, Giani et al. 2005). 
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1.4.2 Anti-IL-1 agents 
Anakinra (Kineret®) is a recombinant form of the human IL-1 receptor 
antagonist which competes with IL-1 when binding to the IL-1RI. It is approved for the 
treatment of rheumatoid arthritis in adult patients failing to respond to one or more 
disease modifying anti-rheumatic drugs (Amgen 2006). 
Anakinra is preferably used in the treatment of systemic onset JIA (SoJIA), a 
subtype of JIA characterized by initial systemic symptoms, including fever and/or rash, 
which precede the development of arthritis by months or even years. Indeed, IL-1β 
expression and production is enhanced in SoJIA patients, especially during the febrile 
phase of the disease. Anakinra treatment led to complete remission in 7 out of 9 SoJIA 
patients who were refractory to other therapies (Pascual, Allantaz et al. 2005). In a 
larger study, 15 out of 20 SoJIA patients showed at least 30% improvement, according 
to the ACR pediatric core set criteria, during the first three months of anakinra 
treatment. Clinical systemic features, including fever and rash, were resolved in 14 
cases within the first three months (Lequerre, Quartier et al. 2008). 
Two newer IL-1 antagonists have recently been approved for the treatment of 
CAPS (cryopyrin-associated periodic syndromes): Canakinumab (Ilaris®), a fully hu-
man IL-1β antibody, and rilonacept (Arcalyst®), a fusion protein consisting of the 
ligand-binding domain of the IL-1 receptor and the IL-1-receptor accessory protein 
bound to human IgG1. 
In a phase II, multicenter, open-label study evaluating dosing and preliminary 
safety and efficacy of canakinumab in 25 SoJIA patients with active systemic features, 
this drug showed a promising preliminary safety and efficacy profile in this limited 
cohort. Indeed, 15 of 25 patients (60%) achieved an ACR 50% improvement, whereas 
4 achieved the inactive disease status (Ruperto, Quartier et al. 2012). Thanks to 
favourable pharmacokinetics and better acceptance from children, it can be speculated 
that canakunimab will replace anakinra in the future. 
 
1.4.3 Anti-IL-6 agents 
Tocilizumab (Actemra®) is a humanized anti-IL-6R monoclonal antibody that 
binds both membrane and soluble IL-6R thereby preventing IL-6 actions during chronic 
inflammation (Mihara, Kasutani et al. 2005). 
Tocilizumab has shown excellent and rapid effectiveness against SoJIA in a 
randomized, double-blind, placebo-controlled, withdrawal phase III trial involving 56 
children (aged 2–19 years) with disease refractory to conventional treatment (Yokota, 
Imagawa et al. 2008). In addition, it has shown to be safe and effective as monotherapy 
in children with polyarticular JIA intractable to conventional methotrexate therapy. 
Interestingly, the effectiveness observed in this study was independent of the serum 
levels of IL-6 before treatment (Imagawa, Yokota et al. 2012). In both studies, no effect 
on growth has been reported, even though anecdotic catch-up growth has been 
observed in 4 children with SoJIA previously (Yokota, Miyamae et al. 2005). 
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2 AIMS 
The general aim of this thesis has been to improve understanding of the local effects of 
pro-inflammatory cytokines at the growth plate level in order to develop more specific 
strategies for treating growth disruption secondary to chronic inflammatory diseases. 
 
More specifically, the aims have been: 
 
1 To study the potential of a TNF-α antagonist to rescue growth independently of the 
pubertal growth spurt, in children with JIA (Paper I). 
 
2 To optimize the use of cytokine antagonists to prevent cytokine-induced growth 
retardation in a model of cultured foetal rat bones (Paper II). 
 
3 To investigate the local production of IL-1β and TNF-α by growth plate 
chondrocytes and their effects on growth in cultured foetal rat bones (Paper III). 
 
4 To investigate the local effects of IL-6 at the growth plate level, in the presence of 
its soluble receptor in a model of cultured foetal rat bones (Paper IV). 
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 RETROSPECTIVE CLINICAL STUDY (PAPER I) 
In the first article, I analyzed in a retrospective way the records of JIA patients 
who had received etanercept treatment in our rheumatologic clinic (Astrid Lindgren 
Children’s Hospital, Solna, Sweden). From 52 records in total, 21 were excluded 
mainly because of interrupted treatment, advanced puberty, or concomitant GH 
therapy. 
As the aim of the study was to examine the contribution of puberty to the effect 
of one year etanercept treatment on longitudinal growth, we collected historical 
information about pubertal signs (breast development in girls and penile/scrotal 
enlargement and/or presence of pubic hair in boys) and obtained the parental self-
reported heights in order to calculate the mid-parental target height for all the patients. 
Once the pubertal status was established, the records were divided into 2 groups, 
the prepubertal patients (n=20), who started etanercept treatment at least 1 year before 
onset of puberty, and the pubertal patients (n=11) which included adolescents in 
early/midpuberty (girls and boys younger than 13.3 and 13.6 years, respectively and 
with pubertal signs and growth velocities ≥ 5 cm/year at start of etanercept treatment).  
To establish the level of growth retardation in the included 31 subjects, the 
child’s height SDS was calculated the year before and the year after the start of 
etanercept treatment according to height SDS standards (Karlberg and Taranger 1976) 
and by use of piecewise linear regression. Furthermore, each child was compared to 
his/her own target height SDS [the child’s height SDS subtracted by the mid-parental 
height SDS (the sum of the father’s and mother’s height plus 13 cm if it is a boy or 
minus 13 cm if it is a girl, all divided by 2)]. 
To evaluate how growth was affected by etanercept, the growth patterns before 
and after treatment were compared in relation to the standard values for age and sex for 
each patient. More precisely, I calculated the change in height SDS (ΔhSDS) the year 
before (from time point -1 yr to 0) and the first year after (time point 0 to +1 yr) the 
treatment was initiated. “Responders” were those patients who improved their ΔhSDS 
after etanercept treatment was initiated (i.e. positive difference) and “Non-responders” 
were those patients who did not improve (i.e. negative or no difference). In this way, 
even the patient who lost height SDS, but to a lesser extent than before etanercept, 
would be considered a “Responder”. On the other hand, a patient who continued to gain 
a height SDS, but to a lesser extent than before the etanercept treatment, was 
considered a “Non-responder”. Catch-up growth is defined as an acceleration of the 
growth rate following a period of growth retardation caused by a secondary deficiency, 
such as acute malnutrition or severe illness (Mosby's Medical Dictionary, 8th edition. © 
2009, Elsevier). In that sense, response in Paper I is related to catch-up growth induced 
by etanercept treatment. 
 
3.2 METATARSAL ORGAN CULTURE (PAPERS II, III AND IV) 
For my experimental studies, the foetal rat metatarsal organ culture model was 
used since, unlike isolated cells in culture, this model preserves the histological 
architecture of the growth plate, and thus, the intercellular interactions and local 
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microenvironments found in vivo. At the same time, such organ cultures facilitate the 
study of direct effects of various compounds in the absence of systemic factors. 
Briefly, the three middle metatarsal bone rudiments were dissected from Sprague 
Dawley rat foetuses on embryonic day 20 (e20) and cultured separately in 24-well 
culture dishes at 37°C in a humidified atmosphere containing 5% CO2. Each well 
contained 0.5 ml MEM supplemented with 0.3 mg/ml L-glutamine, 0.2% BSA, 0.05 
mg/ml ascorbic acid, 1 mM sodium glycerophosphate, 100 U/ml penicillin and 100 
µg/ml streptomycin. The medium was changed every 2-3 days. 
The e20 foetal rat metatarsal bones are cartilage anlagen surrounded by a narrow 
bone collar in the centre. They are around 2.3 mm long at the moment of dissection and 
they increase their length by approximately 50% after 7 days in culture. 
Foetal rat metatarsal bones are ideal to study the actions of cytokines versus 
postnatal bones since they do not present a bone marrow containing cytokine-producing 
cells from the immune system that could interfere with my studies. 
This model was employed in Papers II, III and IV (included in this thesis) to 
study longitudinal bone growth, cytokine production (RT-PCR), expression (IHC) and 
secretion (ELISA), chondrocyte proliferation (BrdU incorporation), apoptosis 
(TUNEL), hypertrophy (Collagen type X IHC) and indirectly, extracellular matrix 
degradation (quantification of GAG released to the medium). 
All studies were approved by the local ethics committee in Stockholm. 
 
3.3 MEASUREMENT OF LONGITUDINAL GROWTH (PAPERS II, III AND 
IV) 
Digital pictures of each metatarsal bone were taken on the first day (designated as 
day 0) and subsequently 2, 5, 7, 9 and 12 days later using a Hamamatsu C4742–95 
digital camera attached to a Nikon SMZ-U microscope. The longitudinal growth of the 
metatarsals was measured by using the Image-Pro® Plus software (Media Cybernetics 
Inc., Berkshire, UK). Growth at the different time-points was calculated as the percent 
increase in bone length from the day of dissection (day 0=baseline) (Papers II and III) 
or growth velocity [bone length increase/ time (µm)/day] (Paper IV). 
 
3.4 CELL PROLIFERATION ASSAY (BRDU) (PAPERS II, III AND IV) 
For this assay, 5-bromo-2’-deoxyuridine (BrdU) was added into the culture 
medium 2.5 hours prior to fixation; in order to let the thymidine analogue, BrdU, be 
incorporated into the newly synthesized DNA by cells entering and progressing 
through the DNA synthesis (S) phase of the cell cycle. Afterwards, bones were 
formaldehyde-fixed, decalcified and paraffin-embedded to prepare serial sections of 
the tissue. Later, the slides were preheated, deparaffinized and rehydrated. Next, 
antigen retrieval was performed to increase the sensitivity of the immunostaining by 
incubating the slides in hot citrate buffer. 
Detection of BrdU-positive cells was performed according to the manufacturer's 
instructions (Amersham Biosciences, Buckinghamshire, UK) as this kit contained a 
specific monoclonal antibody that identified those cells that were proliferating during 
the period of BrdU incubation. As the secondary antibody, the fluorescent conjugated 
antibody FITC was used to detect the bound mouse anti-BrdU antibody, and the 
fluorescent stain DAPI was used to identify the nucleus of all chondrocytes since it 
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binds to the A-T rich regions in DNA in all cells. By use of a fluorescence 
microscope, proliferative cells were identified (FITC positive cells) and the percent of 
the total cell number (DAPI positive cells) was calculated. Eventual positive cells 
within the perichondrium and primary ossification centre were excluded from 
analysis. 
 
3.5 APOPTOSIS ASSAY (TUNEL) (PAPERS II, III AND IV) 
It has been demonstrated that terminal hypertrophic chondrocytes in the GP die 
by apoptosis, characterized by rapid cellular condensation, followed by endothelial cell 
penetration into the vacated lacuna (Farnum and Wilsman 1989). The TUNEL assay 
allows for detection of apoptosis at the individual cell level as the terminal transferase 
TdT catalizes the addition of nucleotides to the 3' terminus of DNA fragments 
generated in response to apoptotic signals. These nucleotides are biotin-labelled and 
can be detected by streptavidin conjugated to Alexa Fluor® 546 (Invitrogen Inc.). By 
use of a fluorescence microscope, apoptotic cells (Alexa positive cells) are identified 
and the percent of the total cell number (DAPI positive cells) is calculated. In my 
studies, positive cells within the perichondrium and primary ossification centre were 
excluded from analysis. 
 
3.6  ALCIAN BLUE BINDING ASSAY (GAG QUANTIFICATION) (PAPERS 
II, III AND IV) 
The ECM of the growth plate cartilage is composed mainly of collagens and 
proteoglycans. Aggrecan is a large aggregating proteoglycan specific for cartilage and 
it consists of a core protein covalently bound to side chains of GAGs, mainly 
chondroitin sulphate, which is characterized by its negatively charged carboxyl and 
sulphate groups (Heinegard and Oldberg 1989). On the other hand, alcian blue is a 
tetravalent cation (basic) dye used to stain acidic polysaccharides. The four charges 
allow the dye to bind to negatively charged polymers such as GAGs at high ionic 
strength. 
In my experiments, the GAGs released into the medium by foetal rat metatarsal 
bones were quantified, as pro-inflammatory cytokines are known to induce ECM 
degradation in articular chondrocytes. I performed the Alcian blue-binding assay 
(Wieslab™ sGAG quantitative kit, Euro-Diagnostica, Sweden) according to the 
manufacturer’s instructions and expressed GAG release in relation to metatarsal bone 
wet weight. 
 
3.7 REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RT-
PCR) (PAPER III) 
This method was used to identify endogenous production of IL-1β and TNF-α 
by growth plate chondrocytes (Paper III). The first step was to extract total RNA from 
snap-frozen cartilaginous parts and whole foetal rat metatarsal bones by use of the 
RNA mini kit (BioRad). This method relies on the property of silica-covered mini 
columns to adsorb nucleic acids depending on the pH and the salt content of the 
buffer used. Briefly, the tissue was homogenized and cells were lysated. After 
addition of alcohol, the samples were applied to the mini columns. Three quick 
washes, which include a DNase I digest, followed. Samples were ready to use after 
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they were eluted with a warmed elution solution into RNase free micro tests tubes 
included in the kit. 
Afterwards, I applied the iScript™ cDNA Synthesis Kit (BioRad, Cat. # 170-
8891) to obtain DNA since it contained Reverse Transcriptase, which is a DNA 
polymerase enzyme that transcribes single stranded RNA into single stranded DNA 
and then synthesizes a second strand of DNA complementary to the reverse-
transcribed single-stranded cDNA after degrading the original mRNA due to its 
RNaseH activity. 
The end-products thus obtained were subjected directly to PCR in a Perkin-
Elmer GeneAmp PCR System 2400. PCR is used to amplify a specific region of a 
DNA strand (the DNA target). The method relies on thermal cycling, consisting of 
cycles of repeated heating and cooling of the reaction for DNA melting and 
enzymatic replication of the DNA. Primers (short DNA fragments) containing 
sequences complementary to the target region along with a DNA polymerase (after 
which the method is named) are key components to enable selective and repeated 
amplification. As PCR progresses, the DNA generated is itself used as a template for 
replication, setting in motion a chain reaction in which the DNA template is 
exponentially amplified. 
 
3.8 IMMUNOHISTOCHEMISTRY (IHC) (PAPERS III AND IV) 
Immunohistochemical stainings were performed to detect endogenous cytokine 
production (Paper III) and collagen type X expression (Papers III and IV) in foetal rat 
metatarsal bones. 
To perform IHC, bones were formaldehyde-fixed, decalcified and paraffin-
embedded to prepare serial sections of the tissue. Later, the slides were preheated, 
deparaffinized and rehydrated. Afterwards, antigen retrieval was performed to increase 
the sensitivity of the immunostaining by incubating the slides in hot citrate buffer. 
Next, inactivation of endogenous peroxidase activity was performed by incubating the 
slides with hydrogen peroxide, as the method for the development of colour uses the 
peroxidase enzymatic system (DAB). In the case of collagen type X IHC, additional 
incubation with hyaluronidase was performed in order to digest the GAG hyaluronan, 
and thereby exposed the antigenic site in the collagen molecule. 
The next step in IHC was the incubation of samples with serum from a species 
unrelated to the primary or secondary antibodies or the tissue in study in order to block 
non-specific hydrophobic interactions. In the case of IL-1β and TNF-α IHC (Paper III), 
an additional blocking step of the endogenous biotin was performed. 
The primary antibodies to detect TNF-α and IL-1β used in Paper III were the 
rabbit anti-rat TNF antibody (U-CyTech BV, Utrecht University, The Netherlands) and 
goat anti-rat IL-1β antibody (AF-501-NA, R&D Systems, Minneapolis, MN) followed 
by appropriate secondary biotin-labeled antibodies: donkey anti-rabbit antibody (705-
066-147) and donkey anti-goat (705-066-147) from Jackson ImmunoResearch Lab, 
West Grove, PA, respectively. In each assay, controls for specificity of the cytokine 
stainings were included, based on parallel staining studies, omitting the primary 
antibodies and using a primary isotype-matched immunoglobulin of irrelevant antigen-
specificity (negative rabbit IgG control, XO936, DAKO, Glostrup, Denmark, DAKO 
Cytomatation, Glostrup, Denmark or goat anti human IL-4, AF-504, R&D Systems). 
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For collagen type X detection in Papers III and IV, the primary antibody used 
was the monoclonal antibody X53 against human recombinant type X (Quartett GmbH, 
Berlin, Germany) as the primary antibody. The polyclonal rabbit anti-mouse 
Immunoglobulins biotiynilated (DAKO) was used as the secondary antibody. 
The complex formed by biotin in the secondary antibodies with avidin and 
horseradish peroxidase in the ABC solution (Vectastain Elite kit, Vector) was later 
identified by the reaction with DAB and hydrogen peroxide, which resulted in a 
permanent dark-brown colour in which the protein of interest was found. The slides 
were counterstained with Mayer’s haematoxylin (Paper III) or Alcian blue (Papers III 
and IV). 
 
3.9 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) (PAPER IV) 
IL-6 production was investigated in the conditioned media of foetal rat metatarsal 
bones treated with IL-1β and/or TNF-α by use of the Quantikine ELISA rat 
immunoassay (R&D systems, Minneapolis, MN) which employs the quantitative 
sandwich enzyme immunoassay technique. A monoclonal antibody specific for rat IL-6 
had been pre-coated onto a microplate. Standards, control, and samples were pipetted 
into the wells and any rat IL-6 present was bound by the immobilized antibody. After 
washing away any unbound substances, an enzyme-linked polyclonal antibody specific 
for rat IL-6 was added to the wells. Following a wash to remove any unbound 
antibody-enzyme reagent, a substrate solution was added to the wells. The enzyme 
reaction yielded a blue product that turned yellow when the Stop Solution was added. 
The intensity of the colour measured was in proportion to the amount of rat IL-6 bound 
in the initial step. The sample values were then read from the standard curve.  
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4 RESULTS AND DISCUSSION 
 
4.1 GROWTH IMPROVEMENT WITH ETANERCEPT IS INDEPENDENT OF 
PUBERTY (PAPER I) 
The aim of my first study was to identify the contribution of anti-TNF therapy on 
longitudinal growth of JIA patients independently of puberty. A previous study in a 
small mixed population (n=7) of prepubertal and pubertal girls with refractory JIA and 
growth retardation demonstrated for the first time that etanercept treatment improved 
both disease activity and growth velocity, highlighting the importance of disease 
control on growth restoration (Schmeling, Seliger et al. 2003). However, it was not 
clear if the catch-up growth observed in those patients was due to the use of etanercept, 
the TNF antagonist, which may have prevented those children from the negative effects 
of this cytokine on growth, or, the fact that most of those children had undergone 
puberty, which is usually accompanied by growth acceleration. It has been shown that 
girls with JIA have a later menarche than both their mothers and the normal female 
population, particularly if they have received GC therapy (Rusconi, Corona et al. 2003). 
I therefore analyzed separately the prepubertal from the pubertal children in my study. 
During the year before instauration of etanercept treatment, height SDS decreased 
by 0.3±0.1 SDS in prepubertal patients (n=20) and by 0.2±0.2 SDS in pubertal patients 
(n=11). In contrast, during the first year of etanercept treatment, height SDS increased 
by 0.2±0.1 SDS (p=0.001 vs. the year before etanercept) in prepubertal patients and by 
0.2±0.1 SDS (p=0.071 vs. the year before etanercept) in pubertal patients. After 
analyzing each individual patient, it was found that 17 of 20 prepubertal and 8 of 11 
pubertal patients were “responders” to etanercept treatment with regards to growth. 
Moreover, the growth response was inversely correlated to the need of intraarticular 
GC injections (p=0.001). 
Taken as a group, the prepubertal patients exhibited catch-up growth; in that 
sense, our results indicate that growth improvement with etanercept is independent of 
puberty. Although the growth improvement in the pubertal group did not reach 
statistical significance in our study, the majority of those patients showed catch-up 
growth after etanercept treatment too, albeit these children were less growth retarded at 
start of etanercept treatment (-1.3±0.3 vs. -2.1±0.3 height SDS in the prepubertal 
group). 
In parallel to the development of the present study, another group in Finland 
confirmed that refractory JIA pre/midpubertal patients treated with etanercept or 
infliximab improved their growth and reduced disease activity. This effect was 
predominant in the most growth-retarded children, who decreased their need of GCs 
after initiation of anti-TNF treatment (Tynjala, Lahdenne et al. 2006). Another study 
has shown that etanercept treatment, with or without methotrexate, contributes to the 
restoration of normal growth in children with JIA (Giannini, Ilowite et al. 2010), 
however, in this study, no consistent effect of disease control on height was observed 
for any of the treatment groups over the course of the study. 
Furthermore, a subsequent study in polyarticular-course JIA patients 
demonstrated that etanercept + methotrexate treatment resulted in a significant increase 
of bone mineral content and lean to fat mass ratio, in contrast to methotrexate treatment 
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only. Improvement of disease activity and a clear tapering of corticosteroid dose were 
observed in both groups. Moreover, decreased IL-6 and increased osteoprotegerin 
plasma levels were observed in the etanercept + methotrexate group (Billiau, Loop et 
al. 2010). 
A common pattern in the previously mentioned studies (Tynjala, Lahdenne et al. 
2006; Billiau, Loop et al. 2010), including this one (Vojvodich, Hansen et al. 2007) was 
the reduction of GC administration as a consequence of the improvement of disease 
activity following etanercept treatment. This observation may suggest that growth 
improvement after etanercept treatment is due to the reduced exposure to GCs, as these 
agents are well known to inhibit longitudinal growth by direct actions at the GP level 
(Chrysis, Ritzen et al. 2003). Additional in vitro experiments testing etanarcept at the 
GP level were needed to understand the cause and effect relationship between 
etanercept and bone growth, and this is what was covered in the next study. 
 
4.2 BIOLOGICAL AGENTS EFFICIENTLY PREVENT CYTOKINE-
INDUCED BONE GROWTH IMPAIRMENT (PAPER II) 
In vitro experiments have demonstrated that IL-1β and TNF-α, two of the main 
cytokines up-regulated during chronic inflammation, exert direct effects on the GP, 
impairing longitudinal bone growth by decreasing chondrocytes’ proliferation and 
hypertrophy as well as increasing apoptosis (Martensson, Chrysis et al. 2004; MacRae, 
Farquharson et al. 2006). Indeed, both IL-1RI and TNF-RI receptors, which mediate 
the actions of IL-1β and TNF-α, respectively, are expressed by GP chondrocytes at all 
levels of differentiation in the foetal rat metatarsal bone (Martensson, Chrysis et al. 
2004). The aim of my second study was to investigate the potential of clinically-used 
biological agents against IL-1β and TNF-α to counteract the growth retardation induced 
by the combination of these two cytokines, and if IGF-I may potentiate such an effect. 
In the present study, I found that the biologic agents, anakinra and etanercept, 
each have the capacity to dose-dependently rescue the growth of cytokine-exposed 
foetal rat metatarsal bones. The biologics also restored chondrocyte proliferation, 
prevented ECM degradation, as well as rescued growth plate chondrocytes from 
undergoing apoptosis. Furthermore, when IGF-I was used in combination with 
etanercept or anakinra, it rescued metatarsal bones from cytokine-induced growth 
retardation in an additive way. 
In the previous study conducted by our group, cytokine antibodies added in 10-
fold excess in relation to the cytokine concentration or IGF-I, could partially reverse the 
deleterious effect of IL-1β plus TNF-α on growth (Martensson, Chrysis et al. 2004). 
However, it has now become evident that the antibodies used had a relatively low 
affinity and that IL-1β or TNF-α signalling was not entirely blocked (R&D Systems 
2009; R&D Systems 2010). Paper II demonstrated that effective blockage of those pro-
inflammatory cytokines with anakinra or etanercept rescues longitudinal bone growth 
and protects growth plate chondrocytes from the deleterious effects of the combination 
of IL-1β plus TNF-α. Nonetheless, the second study also showed that an early 
treatment start with etanercept leads to a more efficient growth rescuing effect than if 
introduced after the initiation of cytokine exposure. 
Another study in postnatal mouse metatarsal bones, where growth retardation 
was induced by culturing them with synovial fluid rich in cytokines (including IL-1β 
and TNF-α) from a JIA patient, failed to restore growth despite co-incubation with 
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IGF-I or specific antibodies against IL-1β and TNF-α in adequate concentration. This 
suggested that other factors in the biological fluid played a predominant role in the 
growth inhibition observed (Macrae, Wong et al. 2007). The use of synovial fluid 
instead of individual cytokines in those experiments brought one closer to the in vivo 
situation, but the simplified experimental model employed in Paper II let us observe the 
direct harmful effects of IL-1β and TNF-α at the GP level as well as the benefits of 
inhibiting them by use of biological drugs. 
Growth improvement after anti-TNF therapy is associated to a reduction of GC 
administration in JIA patients (Tynjala, Lahdenne et al. 2006; Vojvodich, Hansen et al. 
2007; Billiau, Loop et al. 2010) and it was hypothesized that anti-TNF treatment may 
act indirectly to restore growth in those subjects by reducing exposure to GCs or by 
systemic effects at the GH/IGF-I axis (Macrae, Wong et al. 2007). However, Paper II 
demonstrates that etanercept prevents the direct actions of TNF-α at the GP level. 
The dose- and time-dependent effect of etanarcept in cytokine-exposed metatarsal 
bones suggests that a higher dose and/or an earlier introduction of etanercept treatment 
might more effectively prevent growth failure in children with chronic inflammatory 
diseases. In addition, the dose-dependent growth rescuing effect of anakinra in 
cytokine-exposed metatarsal bones suggests that therapies targeting IL-1-actions have 
the potential to rescue bone growth in paediatric patients suffering from chronic 
inflammatory disorders. However, the results gathered are only experimental and 
thereby need to be validated in controlled clinical studies. 
In Paper II, the strategy of combining the growth promoting agent IGF-I with 
etanercept or anakinra was also explored; this strategy improved the growth of 
cytokine-treated foetal rat metatarsal bones in an additive way. IGF-I is today clinically 
available as mecasermin (recombinant human IGF-1), but it is only approved for the 
long term treatment of growth failure in children with severe primary IGF-deficiency 
(Fintini, Brufani et al. 2009). Based on the present data, we speculate that combination 
therapy with etanercept and IGF-I might effectively rescue bone growth in paediatric 
patients with chronic inflammatory diseases. However, such a treatment must be 
regarded experimental and should only be initiated within clinical trials carefully 
monitoring any adverse reactions including immunologic interactions. 
 
4.3 IL-1β AND TNF-α ARE PRODUCED BY GROWTH PLATE 
CHONDROCYTES (PAPER III) 
In Paper II, it was demonstrated that anakinra and etanercept have the capacity to 
rescue cultured foetal rat metatarsal bones from cytokine-induced growth impairment. 
Interestingly, when a high concentration of anakinra or etanercept was added in 
combination with IL-1β and TNF-α, bone growth even slightly exceeded that in control 
bones. Based on those findings, it was then hypothesized that pro-inflammatory 
cytokines might be endogenously produced by growth plate chondrocytes acting locally 
to modulate normal bone growth. To test this hypothesis, the local cytokine expression 
in cultured foetal rat metatarsal bones was investigated and then the bones were 
challenged to anakinra and/or etanercept while the longitudinal bone growth was 
monitored. 
In this study, it was found that IL-1β and TNF-α were indeed produced by growth 
plate chondrocytes, and that suppression of locally produced TNF-α and/or IL-1β led to 
improved bone growth. This is the first demonstration of a functional role of locally 
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expressed IL-1β and TNF-α in the normal growth plate. Other studies have found that 
IL-1β and TNF-α are locally expressed by articular chondrocytes in healthy young 
human cartilage (Middleton, Manthey et al. 1996; Moos, Fickert et al. 1999) which 
supports these findings. 
Mechanistic studies identified different roles for the endogenously produced IL-
1β and TNF-α in the normal regulation of longitudinal bone growth. For instance, 
etanercept increased proliferation within the PZ, and cell number within the RZ, 
although proliferation was decreased in this zone. These results suggest that 
endogenous TNF-α might decrease chondrocyte proliferation within the PZ, but 
increase proliferation within the RZ. In line with these findings, TNF-α reduced 
chondrocyte proliferation in the differentiated phenotype of the murine ATDC5 
chondrogenic cell line (MacRae, Farquharson et al. 2006) whereas it stimulated [3H] 
thymidine incorporation in the undifferentiated phenotype of the same cell line 
(Horiguchi, Akiyama et al. 2000). Furthermore, anakinra treatment tended to increase 
cell density within the HZ while etanercept had an opposite effect. Altogether, I believe 
that endogenously produced TNF-α and IL-1β may act through different mechanisms to 
suppress longitudinal bone growth by selectively targeting different zones of the 
growth plate. 
Morphometric analysis demonstrated that anakinra and etanercept induced non-
significant increments of HZ area and height as well as a slight reduction of GAG 
released into the medium. In combination, those effects were synergistic in an additive 
way. These results suggest that endogenously produced IL-1β and TNF-α play a normal 
role to control the height of the HZ and to induce ECM degradation. These findings are 
supported by previous observations in postnatal mouse metatarsal bones, in which IL-
1β and/or TNF-α inhibited bone growth, an effect which was accompanied by a 
reduction of the size of the hypertrophic growth plate zone (MacRae, Farquharson et al. 
2006). On the other hand, cytokines, such as IL-1α and TNF-α, have been shown to 
stimulate chondrocyte production of MMP-13 (Shi, Schmitt-Talbot et al. 2004), known 
to be important for the ossification of the hypertrophic zone during endochondral bone 
formation (Inada, Wang et al. 2004). 
Although our findings are significant and attempts have been made to include 
appropriate controls, the present study has some limitations. First of all, we have 
applied an ex vivo model. In an in vivo model, there may be counter-regulatory 
feedback mechanisms, which could reduce the impact of local blockage of cytokine 
actions in the growth plate. Secondly, our studies have been performed in foetal bones. 
It is possible that endogenously produced pro-inflammatory cytokines only play a 
regulatory role during bone development, and therefore are of minor importance for 
postnatal growth. Lastly, we have studied rat bones and differences between the species 
may exist. 
 
4.4 IL-6 ACTS DIRECTLY AT THE GROWTH PLATE LEVEL TO 
DECREASE LONGITUDINAL BONE GROWTH (PAPER IV) 
IL-6 can be found in high concentrations in serum and synovial fluid of JIA 
patients (Kutukculer, Caglayan et al. 1998; Yilmaz, Kendirli et al. 2001; Saxena, 
Aggarwal et al. 2005; Macrae, Wong et al. 2007), and over-expression of this cytokine 
in transgenic mice results in impaired bone growth that involves alterations in the 
GH/IGF-I axis (De Benedetti, Alonzi et al. 1997). In contrast to IL-1β and TNF-α, 
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direct effects of IL-6 on GP chondrocytes were not proven (Martensson, Chrysis et al. 
2004; MacRae, Farquharson et al. 2006). The present study aimed to investigate the 
direct effects of IL-6 in foetal rat metatarsal bones, in the presence of the soluble IL-6 
receptor, IL-6Rα. 
In Paper IV, it was found that IL-6 decreased longitudinal bone growth when IL-
6Rα was present in the culture medium. Mechanistic studies revealed a significant 
reduction in the PZ’s cell density associated with non-significant reduction of 
chondrocyte proliferation and increased apoptosis in this zone. In addition, IL-6 
decreased HZ height and area together with a non-significant increase in GAG release. 
Supporting these findings, previous studies have shown that mice that over-express IL-
6 are smaller than their wild-type littermates, and they also exhibit reduced HZs (De 
Benedetti, Rucci et al. 2006). Moreover, the decreased chondrocyte differentiation 
observed in my studies is supported by previous findings in the ATDC5 chondrogenic 
cell line, in which IL-6 inhibited cartilaginous nodule formation and markedly reduced 
the expression of type II collagen, aggrecan and type X collagen when introduced early 
during culture (Nakajima, Naruto et al. 2009). 
In Paper IV, the interactions between IL-6 and the already-studied IL-1β and 
TNF-α were investigated at the GP level. I found that IL-6+IL-6Rα synergized with 
either IL-1β or TNF-α to further decrease HZ height and area, and ultimately, bone 
growth. Moreover, IL-6 and its soluble receptor, together with IL-1β, reduced PZ cell 
density and in combination with TNF-α, it reduced RZ area. However, when IL-6 was 
added to the already detrimental IL-1β+TNF-α combination, bone growth was not 
further decreased. 
To further explore the suppression of IL-6+IL-6Rα activity in the presence of IL-
1β+TNF-α, I investigated IL-6 production by foetal rat metatarsal bones treated with 
IL-1β and/or TNF-α and found that even though production of IL-6 mediated by IL-1β 
or TNF-α alone did not differ from the control, in combination, both cytokines 
synergistically increased the levels of IL-6 in the conditioned media. In an attempt to 
block the actions of endogenously-produced IL-6, I treated foetal rat metatarsal bones 
with the IL-6 antibody added to the detrimental IL-1β+TNF-α combination for 12 days, 
but growth could not be re-constituted (data not shown). 
It has been shown before that both IL-1β and TNF-α stimulates IL-6 mRNA 
expression in gingival fibroblasts by a mechanism involving the MAPK, yet not the 
NF-kB signalling pathway, as only pharmacological inhibitors against the p38 and the 
JNK MAPKs significantly inhibited IL-1β and TNF-α -induced mRNA expression of 
IL-6 (Palmqvist, Lundberg et al. 2008). Moreover, experiments in the SW982 human 
synovial sarcoma cell line have demonstrated that IL-1β stimulates the production of 
IL-6, whereas IL-6 plus its soluble receptor stimulate production of IL-1RI in those 
cells. Interestingly, SW982 cells treated with IL-1β plus the soluble IL-6R only, 
enhances IL-1β-mediated MMP production, as IL-6 is already present in the medium, 
which explains the synergism observed between IL-1β and IL-6 (Suzuki, Hashizume et 
al. 2010). Based on this knowledge, the synergism between IL-1β plus IL-6+IL-6Rα 
observed in Paper IV can be explained by an increased sensitivity to IL-1β in the foetal 
rat metatarsal bones mediated by IL-6+IL-6Rα. In the same way, the increased 
production of endogenous IL-6 mediated by IL-1β+TNF-α treatment in metatarsal 
bones may enhance the sensitivity to IL-1β, thereby exhibiting synergistic effects. 
However, addition of IL-6+IL-6Rα to the already nocive IL-1β+TNF-α treatment might 
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not contribute anymore to the enhancement of IL-1RI expression, or it may encounter a 
limitation in the IL-1β substrate. 
Several clinical studies in which anti-TNF treatment restored growth in children with 
JIA found that growth improvement was associated with a reduction of circulating IL-6 
(Schmeling, Seliger et al. 2003; Billiau, Loop et al. 2010). Tocilizumab, a humanized 
anti-IL-6R monoclonal antibody that prevents IL-6 from binding to IL-6R (Mihara, 
Kasutani et al. 2005), has been shown to be safe and effective when used in 
combination with methotrexate to treat patients with moderate to severe active RA who 
are responding inadequately or who are intolerant to TNF antagonists (Emery, 
Keystone et al. 2008). The use of tocilizumab in children with SoJIA has shown a 
sustained clinical improvement and a favourable risk-benefit profile. The findings of 
this study might represent a step forward in the control of a disease that has been 
previously proven as difficult to manage (Yokota, Imagawa et al. 2008). Nevertheless, 
more experimental and clinical studies are needed in order to determine the 
contribution of this or future anti-IL-6 drugs, to counteract growth retardation in JIA 
patients.  
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5 CONCLUSIONS 
 
From the individual studies, the following conclusions have been reached: 
 
Etanercept is capable to improve linear bone growth and reduce the need for 
intraarticular glucocorticoid injections in a majority of prepubertal and pubertal JIA 
patients who are non-responsive to conventional therapy. The minority of JIA patients 
who do not respond to anti-TNF treatment may be candidates for therapeutic agents 
that target other pro-inflammatory cytokines or therapies targeting the GH/IGF-I axis. 
(Paper I) 
 
Anakinra and etanercept dose-dependently improve in vitro growth of foetal rat 
metatarsal bones exposed to pro-inflammatory cytokines. From this finding, it can be 
speculated that increased dosing of biological agents might be clinically effective to 
improve bone growth in children with chronic inflammatory diseases. The experimental 
data also suggest that an alternative approach combining treatment with biologics and 
IGF-I may be effective to further improve growth in those patients. However, such 
treatment strategies need to be evaluated within controlled clinical trials. (Paper II) 
 
Pro-inflammatory cytokines IL-1β and TNF-α are produced within the growth 
plate of foetal rat metatarsal bones and suppression of their activities leads to improved 
longitudinal bone growth. Further studies may clarify if anti-cytokine therapy has the 
capacity to increase postnatal bone growth in vivo. (Paper III) 
 
IL-6 is endogenously produced by cultured foetal rat metatarsal bones upon 
stimulation with IL-1β and TNF-α. Added exogenously, IL-6, in the presence of its 
soluble receptor, decreases in vitro bone growth demonstrating direct actions of IL-6 at 
the growth plate level. Moreover, it synergizes with IL-1β and TNF-α to further 
decrease bone growth. (Paper IV) 
 
In conclusion, the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, up-
regulated during chronic inflammatory diseases in children, exert direct effects on 
growth plate chondrocytes and interact in a synergistic way to decrease longitudinal 
bone growth.  Biological agents targeting any of these cytokines may prevent damage 
to the growth plate in those patients while at the same time the inflammatory condition 
itself ameliorates. In addition, IGF-I treatment may be effective to further improve 
growth in those patients; however, such treatment strategies need to be evaluated within 
controlled clinical trials. 
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